RICHARD H. SCHELLER - 16 May 2022 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role: Director
Signature: /s/ Brian C. Stephenson, Attorney-in-Fact
Issuer symbol: BBIO
Transactions as of: 16 May 2022
Net transactions value: -$8,829
Form type: 4
Filing time: 18 May 2022, 16:09:19 UTC
Previous filing: 15 Mar 2022
Next filing: 08 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BBIO	Common Stock	Options Exercise		+3,195	+7%		49,055	16 May 2022	Direct	F1
transaction	BBIO	Common Stock	Tax liability	$8,829	-1,310	-2.7%	$6.74^*	47,745	16 May 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BBIO	Restricted Stock Units	Options Exercise	$0	-3,195	-12%	$0.000000	22,371	16 May 2022	Common Stock	3,195		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2	Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,195 shares of Common Stock underlying the Reporting Person's RSUs.
F3	The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.